Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Newsoara BioPharma Expands Global Rights to vTv’s PDE4 Inhibitor HPP737 in $135 Million Deal

Fineline Cube Feb 11, 2026
Company Deals Medical Device

Siemens Healthineers Partners with Northwestern Medicine to Advance Precision Cancer Care

Fineline Cube Feb 11, 2026
Company Deals

Cascade Pharma Raises $72 Million to Advance MASH and Obesity Pipeline to Phase III

Fineline Cube Feb 11, 2026
Company Deals

uBriGene Biosciences Partners with Innovec Biotherapeutics on AAV Gene Therapy for Hereditary Eye Diseases

Fineline Cube Feb 11, 2026
Company Deals

China Resources Pharma to Divest 17.87% Stake in Tianmai Bio for $205 Million

Fineline Cube Feb 11, 2026
Policy / Regulatory

FDA Cracks Down on Compounded GLP-1 APIs; Novo Nordisk Sues Hims & Hers for Patent Infringement

Fineline Cube Feb 11, 2026
Company Drug

SciClone’s Tasurgratinib NDA Accepted by NMPA for FGFR2+ Biliary Tract Cancer

Fineline Cube Feb 11, 2026
Company Drug

Hengrui Pharma’s Trastuzumab Rezetecan Filing Accepted for HER2+ Colorectal Cancer Indication

Fineline Cube Feb 11, 2026
Company Deals

MDHC Life Technologies Secures Series C++ Funding to Boost Consumer Healthcare and Life Sciences

Fineline Cube Dec 12, 2024

China-based Contract Development Manufacturing Organization (CDMO) MDHC Life Technologies (Kunshan) Co.,Ltd has reportedly raised hundreds...

Company

Bayer AG’s Shanghai Co.Lab to Host Epigenic Therapeutics and Peers for CGT Innovation

Fineline Cube Dec 12, 2024

Germany-based Bayer AG (ETR: BAYN) has announced that Chinese companies Epigenic Therapeutics, Shanghai Immunocan Biotech...

Company Drug

AstraZeneca’s Lynparza Shows Sustained Improvements in OlympiA Phase III Study

Fineline Cube Dec 12, 2024

UK pharmaceutical major AstraZeneca (AZ; NASDAQ: AZN) has updated data from the Phase III OlympiA...

Company Drug

Sanofi Receives FDA Fast-Track Designation for Influenza and COVID-19 Combo Vaccine Candidates

Fineline Cube Dec 12, 2024

Sanofi (NASDAQ: SNY) has announced that it has received Fast-Track Designations from the US Food...

Company Deals

Youjia Biomedical and Livzon Pharmaceutical Group Ink Licensing Deal for siRNA Drug

Fineline Cube Dec 12, 2024

China-based Youjia (Hangzhou) Biomedical Technology Co., Ltd. has signed a licensing agreement with compatriot firm...

Company Deals

Bayer AG to Acquire HiDoc Technologies and Launch Digital Health App Cara Care

Fineline Cube Dec 12, 2024

Germany-based Bayer AG (ETR: BAYN) has announced plans to acquire HiDoc Technologies GmbH in the...

Company Drug

Eli Lilly’s Imlunestrant Reduces Disease Progression in ER+/HER2- Advanced Breast Cancer: EMBER-3 Study

Fineline Cube Dec 12, 2024

US pharmaceutical major Eli Lilly and Company (NYSE: LLY) has published results from the Phase...

Policy / Regulatory

Shanghai Unveils Action Plan and Fund for Biopharma M&A Activities

Fineline Cube Dec 11, 2024

The Shanghai Municipal People’s Government has released the “Action Plan for Supporting Mergers and Acquisitions...

Company Deals

Fresenius Kabi Partners with Ori Biotech to Integrate IRO Platform with Cell Processing Systems

Fineline Cube Dec 11, 2024

Germany-based Fresenius Kabi, a leading name in healthcare, has struck an accord with Ori Biotech...

Company Drug

Arvinas and Pfizer Present Positive TACTIVE-U Sub-Study Data at SABCS 2024

Fineline Cube Dec 11, 2024

Partners Arvinas, Inc. (NASDAQ: ARVN) and Pfizer Inc. (NYSE: PFE) have jointly presented preliminary data...

Company Deals

GSK Enters Multi-Program Partnerships with Relation Therapeutics for Fibrotic Diseases and Osteoarthritis

Fineline Cube Dec 11, 2024

UK-based pharmaceutical giant GlaxoSmithKline (GSK, NYSE: GSK) has formed two multi-program strategic partnerships with compatriot...

Company Drug

Novartis’ Kisqali Shows Sustained Efficacy in NATALEE Study at SABCS 2024

Fineline Cube Dec 11, 2024

Swiss pharmaceutical giant Novartis (NYSE: NVS) presented updated results from the pivotal Phase III NATALEE...

Company Drug

Legend Biotech’s Carvykti Demonstrates High MRD Negativity Rates in Phase III CARTITUDE-4 Trial

Fineline Cube Dec 11, 2024

China-based Legend Biotech Corporation (NASDAQ: LEGN) has released new data on minimal residual disease (MRD)...

Company Drug

Huadong Medicine’s Arcalyst Receives NMPA Approval for Recurrent Pericarditis Treatment

Fineline Cube Dec 11, 2024

China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced receiving another indication approval from the...

Company Drug

IMEIK Technology Receives NMPA Approval for Recombinant Human Hyaluronidase Clinical Study

Fineline Cube Dec 11, 2024

China-based IMEIK Technology Development Co., Ltd (SHE: 300896) has announced receiving approval from the National...

Company Drug

Patronus Biotech’s RSV Vaccine LYB005 Receives NMPA Approval for Clinical Study

Fineline Cube Dec 11, 2024

Guangzhou Patronus Biotech Co., Ltd., a vaccine start-up specializing in respiratory and infectious diseases, has...

Company Drug

Shanghai Pharmaceuticals’ SRD4610 Receives FDA Orphan Drug Designation for ALS Treatment

Fineline Cube Dec 11, 2024

China’s Shanghai Pharmaceuticals (SPH; HKG: 2607; SHA: 601607) has announced that the US Food and...

Company Drug

Sperogenix Therapeutics’ Agamree Receives NMPA Approval for Duchenne Muscular Dystrophy Treatment

Fineline Cube Dec 11, 2024

China-based rare disease specialist Sperogenix Therapeutics Limited has announced receiving marketing approval from the National...

Policy / Regulatory

Beijing Expands Medical Insurance Sharing to Near Relatives with New Policy

Fineline Cube Dec 11, 2024

The Beijing Municipal Medical Insurance Bureau has released a notification that significantly expands the scope...

Company Drug

Jiangsu Hengrui Pharmaceuticals Secures NMPA Approvals for SHR-4394 and HRS-3802 Clinical Trials

Fineline Cube Dec 11, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has announced receiving separate clinical trial approvals from...

Posts pagination

1 … 205 206 207 … 623

Recent updates

  • Newsoara BioPharma Expands Global Rights to vTv’s PDE4 Inhibitor HPP737 in $135 Million Deal
  • Siemens Healthineers Partners with Northwestern Medicine to Advance Precision Cancer Care
  • SciClone’s Tasurgratinib NDA Accepted by NMPA for FGFR2+ Biliary Tract Cancer
  • Cascade Pharma Raises $72 Million to Advance MASH and Obesity Pipeline to Phase III
  • Hengrui Pharma’s Trastuzumab Rezetecan Filing Accepted for HER2+ Colorectal Cancer Indication
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Newsoara BioPharma Expands Global Rights to vTv’s PDE4 Inhibitor HPP737 in $135 Million Deal

Company Deals Medical Device

Siemens Healthineers Partners with Northwestern Medicine to Advance Precision Cancer Care

Company Drug

SciClone’s Tasurgratinib NDA Accepted by NMPA for FGFR2+ Biliary Tract Cancer

Company Deals

Cascade Pharma Raises $72 Million to Advance MASH and Obesity Pipeline to Phase III

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.